Deer Timothy R, Pope Jason E, Hayek Salim M, Lamer Tim J, Veizi Ilir Elias, Erdek Michael, Wallace Mark S, Grider Jay S, Levy Robert M, Prager Joshua, Rosen Steven M, Saulino Michael, Yaksh Tony L, De Andrés Jose A, Abejon Gonzalez David, Vesper Jan, Schu Stefan, Simpson Brian, Mekhail Nagy
Center for Pain Relief, Charleston, WV, USA.
Summit Pain Alliance, Santa Rosa, CA, USA.
Neuromodulation. 2017 Feb;20(2):155-176. doi: 10.1111/ner.12579. Epub 2017 Jan 2.
Intrathecal therapy is an important part of the pain treatment algorithm for chronic disease states. The use of this option is a viable treatment strategy, but it is inherent for pain physicians to understand risk assessment and mitigation. In this manuscript, we explore evidence and mitigating strategies to improve safety with intrathecal therapy.
A robust literature search was performed covering January 2011 to October 9, 2016, in PubMed, Embase, MEDLINE, Biomed Central, Google Scholar, Current Contents Connect, and International Pharmaceutical Abstracts. The information was cross-referenced and compiled for evidence, analysis, and consensus review, with the intent to offer weighted recommendations and consensus statements on safety for targeted intrathecal therapy delivery.
The Polyanalgesic Consensus Conference has made several best practice recommendations to improve care and reduce morbidity and mortality associated with intrathecal therapy through all phases of management. The United States Prevention Service Task Force evidence level and consensus strength assessments are offered for each recommendation.
Intrathecal therapy is a viable and relatively safe option for the treatment of cancer- and noncancer-related pain. Continued research and expert opinion are required to improve our current pharmacokinetic and pharmacodynamic model of intrathecal drug delivery, as this will undoubtedly improve safety and efficacy.
鞘内治疗是慢性病疼痛治疗方案的重要组成部分。采用这种治疗方法是一种可行的治疗策略,但疼痛科医生必须了解风险评估和风险缓解措施。在本论文中,我们探讨提高鞘内治疗安全性的证据和缓解策略。
在PubMed、Embase、MEDLINE、生物医学中心、谷歌学术、《现刊目次》和《国际药学文摘》中进行了全面的文献检索,检索时间跨度为2011年1月至2016年10月9日。对信息进行交叉引用和整理,以获取证据、进行分析并进行共识审查,目的是针对靶向鞘内治疗给药的安全性提供加权建议和共识声明。
多模式镇痛共识会议提出了多项最佳实践建议,以在管理的各个阶段改善护理并降低与鞘内治疗相关的发病率和死亡率。为每项建议提供了美国预防服务工作组的证据水平和共识强度评估。
鞘内治疗是治疗癌症相关和非癌症相关疼痛的一种可行且相对安全的选择。需要持续的研究和专家意见来改进我们目前的鞘内给药药代动力学和药效学模型,因为这无疑将提高安全性和疗效。